Drug Development

U.S. FTC approves global agreement signed by Isotechnika and Roche

Published in Blood Weekly, June 6th, 2002

Joseph Koziak, executive vice president of Isotechnika, Inc., reported that the United States Federal Trade Commission has approved the agreement for the global codevelopment of Isotechnika's transplant drug, ISA(TX)247, recently signed by Isotechnika and Roche.

The granting of this regulatory approval enables the two companies to move forward with their plans to advance the clinical development and commercialization of ISA(TX)247.

"This approval is great news for Isotechnika and Roche and for transplantation patients around the globe" states Koziak. "This judgment validates the continuing need in the market place and the world transplant community...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-06-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry